Network Intervention, a Method to Address Complex Therapeutic Strategies

Objective: Network-based approaches emerged as powerful tools for studying complex diseases. Our intention in this article was to raise awareness of the benefits of new therapeutic strategy in biological networks context and provide an introduction to this topic. Methods: This article will discuss the rational for network intervention, and outline some of the important aspects of deciphering targets activities in the network and future embodiments of network intervention. We also present examples of network intervention based on the strategies these approaches use. Results: Network intervention seeks for target combinations to perturb a specific subset of nodes in disease networks to inhibit the bypass mechanisms at systems level. Experimental results derived from our studies are discussed, with conclusions that lead to future research directions. A simple diagram is designed to give a way to find the minimum number of external input required for a network intervention based on the graph theory and get the analytical value of the least input. Conclusion: Creating network intervention that addresses blindness and unthinking action in this way could, therefore, provide more benefit than multi-target therapy. We hope that this article will give readers an appreciation for a new therapeutic strategy that has been proposed for improving clinical benefit by adopting network-based approaches as well as insight into their properties.

[1]  S. Kasif,et al.  Network-Based Analysis of Affected Biological Processes in Type 2 Diabetes Models , 2007, PLoS genetics.

[2]  P. Aloy,et al.  A network medicine approach to human disease , 2009, FEBS letters.

[3]  Doheon Lee,et al.  Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.

[4]  Derong Liu,et al.  Data-Based Controllability and Observability Analysis of Linear Discrete-Time Systems , 2011, IEEE Transactions on Neural Networks.

[5]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[6]  Thilo Gross,et al.  Self-organized criticality as a fundamental property of neural systems , 2014, Front. Syst. Neurosci..

[7]  Alan Talevi,et al.  Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..

[8]  Richard E. Neapolitan,et al.  Discovering causal interactions using Bayesian network scoring and information gain , 2016, BMC Bioinformatics.

[9]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[10]  P. Clemons,et al.  Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.

[11]  M. Sen,et al.  Wnt signalling in rheumatoid arthritis. , 2005, Rheumatology.

[12]  C. Rosenberg Contested Boundaries psychiatr y , disease , and diagnosis , 2006 .

[13]  Henrik Madsen,et al.  A New Reduced Rank Square Root Kalman Filter for Data Assimilation in Mathematical Models , 2003, International Conference on Computational Science.

[14]  Chi Zhang,et al.  Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine , 2016, Chinese Journal of Integrative Medicine.

[15]  Balasubramaniam Natarajan,et al.  Epidemic Threshold of an SIS Model in Dynamic Switching Networks , 2015, IEEE Transactions on Systems, Man, and Cybernetics: Systems.

[16]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[17]  E. Sorkin,et al.  Enoxaparin , 2012, Drugs.

[18]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[19]  E. Montgomery,et al.  Classification and pathology. , 2008, The Surgical clinics of North America.

[20]  Ulrik Brandes,et al.  Biological Networks , 2013, Handbook of Graph Drawing and Visualization.

[21]  A. Lu,et al.  Current situation and progress in integrative medicine in China , 2008, Chinese journal of integrative medicine.

[22]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[23]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[24]  Tero Aittokallio,et al.  Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles , 2014, Current pharmaceutical design.

[25]  Hideki Yamamoto,et al.  Axin, a Negative Regulator of the Wnt Signaling Pathway, Directly Interacts with Adenomatous Polyposis Coli and Regulates the Stabilization of β-Catenin* , 1998, The Journal of Biological Chemistry.

[26]  Raoul-Martin Memmesheimer,et al.  Self-organized criticality in a model for developing neural networks , 2011, BMC Neuroscience.

[27]  A. Giuliani,et al.  Why so few drug targets: a mathematical explanation? , 2011, Current computer-aided drug design.

[28]  W. Zhou,et al.  Controllability and Observability of Fractional Linear Systems with Two Different Orders , 2014, TheScientificWorldJournal.

[29]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[30]  Bin Yan,et al.  CMGRN: a web server for constructing multilevel gene regulatory networks using ChIP-seq and gene expression data , 2014, Bioinform..

[31]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[32]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[33]  D. Wernicke,et al.  The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis , 2006, Autoimmunity.

[34]  H. Kubinyi Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[35]  Shengwu Xiong,et al.  InDel marker detection by integration of multiple softwares using machine learning techniques , 2016, BMC Bioinformatics.

[36]  P. Robinson Classification and coding of rare diseases: overview of where we stand, rationale, why it matters and what it can change , 2012, Orphanet Journal of Rare Diseases.

[37]  Thibault Liard,et al.  A Kalman rank condition for the indirect controllability of coupled systems of linear operator groups , 2017, Math. Control. Signals Syst..

[38]  Xia Jiang,et al.  Learning Predictive Interactions Using Information Gain and Bayesian Network Scoring , 2015, PloS one.

[39]  C. Rosenberg Contested Boundaries: psychiatry, disease, and diagnosis , 2006, Perspectives in biology and medicine.